Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetic Response to BPI in Burns

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Ages 13 years to 60 years old~* Sustained partial-thickness or full-thickness burn greater than 20% and less than 41% TBSA~* Parental consent (if subject is less than 18 years old) or individual (if subject is equal to or older than 18) signed, informed consent.~* Able to start BPI in infusion within 8 hours of burn injury.~Exclusion Criteria:~* Age \> 61.~* Inhalational injury requiring mechanical ventilation.~* Partial and full thickness burns totaling \> 41% total body surface area~* Cardiac dysfunction, defined as the presence of any of the following:~  1. New York Heart Class 3 or 4 heart failure.~ 2. Unstable angina or acute myocardial infarction.~ 3. Left ventricular ejection fraction known to be \< 35%.~* Electrical or lightening induced burn injury or any injury that required cardio-pulmonary resuscitation.~* Concomitant non-burn trauma with an ISS \> 9.~* Non-survivable injury secondary to burn size - patients made DNR or comfort care due to burn size.~* Patients with known causes of immunosuppression:~  1. Known history of HIV/AIDS~ 2. Chronic steroid use for underlying medical conditions (equivalent to 15 mg prednisone/day).~ 3. Active oncolytic therapy for known malignancy~* Known or suspected pregnancy~* Known allergy to rBPI21

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- BPI infusion group (Type: EXPERIMENTAL): BPI will be infused by bolus for 30 minutes followed by continuous infusion for 47.5 hours

Based on this trial design, predict the completion outcome and termination type (if applicable).